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Abstract Idiopathic pulmonary fibrosis (IPF) is a rare and
devastating lung disease of unknown aetiology. Genetic
variations in the IL1RN gene, encoding the interleukin-1
receptor antagonist (IL-1Ra), have been associated with
IPF susceptibility. Several studies investigated the variable
number tandem repeat (VNTR) or single nucleotide poly-
morphisms rs408392, rs419598 and rs2637988, with vari-
able results. The aim of this study was to elucidate the
influence of polymorphisms in IL1RN on IPF susceptibility
and mRNA expression. We performed a meta-analysis of
the five case–control studies that investigated an IL1RN
polymorphism in IPF in a Caucasian population. In addition,
we investigated whether IL1RN mRNA expression was
influenced by IL1RN polymorphisms. The VNTR,
rs408392 and rs419598 were in tight linkage disequilibrium,
with D′ > 0.99. Furthermore, rs2637988 was in linkage
disequilibrium with the VNTR (D′ 0 0.90). A haploblock
of VNTR*2 and the minor alleles of rs408392and rs419598
was constructed. Meta-analysis revealed that this VNTR*2
haploblock is associated with IPF susceptibility both with an
allelic model (odds ratio01.42, p00.002) and a carriership
model (odds ratio01.60, p00.002). IL1RN mRNAexpression
was significantly influenced by rs2637988, with lower levels
found in carriers of the (minor) GG genotype (p<0.001).
From this meta-analysis, we conclude that the VNTR*2 hap-
loblock is associated with susceptibility to IPF. In addition,
polymorphisms in IL1RN influence IL-1Ra mRNA expres-
sion, suggesting that lower levels of IL-1Ra predispose to
developing IPF. Together these findings demonstrate that the
cytokine IL-1Ra plays a role in IPF pathogenesis.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing
lung disease with unknown cause and a median survival of
only 2.5 to 3.5 years (Gribbin et al. 2006; Mapel et al. 1998;
Rudd et al. 2007). The disease is characterised by fibroblast
growth, extracellular matrix deposition and remodelling of
alveolar tissue, thereby disabling gas exchange across the
alveolar epithelium (ATS/ERS 2002). IPF is a rare disease
with a prevalence of 14 per 100,000 persons, but the inci-
dence continues to rise and it is now an important cause of
respiratory mortality (Navaratnam et al. 2011; Raghu et al.
2006). Familial and ethnic clustering support the theory that
genetic variations influence IPF disease susceptibility, and
identification of the genes involved can increase understand-
ing of this complex disease (Grutters and du Bois 2005).
Furthermore, because no effective treatment for IPF is avail-
able at present, genetic analysis may also reveal a novel
target for therapy.
Interleukin (IL)-1 is a proinflammatory and profibrotic
cytokine that exists in two forms: IL-1α and IL-1β.
Interleukin-1 receptor antagonist (IL-1Ra) is an inhibitor
IL-1 by competitive binding to the IL-1 receptor. The IL1RN
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susceptibility (Whyte et al. 2000). Genetic variations in
IL1RN, IL1A and IL1B have been associated with ulcerative
colitis, gastric cancer and rheumatoid arthritis (Lee et al.
2009; Peleteiro et al. 2010; Queiroz et al. 2009). Variations
in these genes can modulate the effectiveness of IL-1 signal-
ling and thereby predispose to disease.
Several polymorphisms in IL1RN have been investigated in
IPF case–control studies. Whyte et al. showed a significant
association between IPF susceptibility and the single nucleo-
tide polymorphism (SNP) rs419598 (also known as +2018) in
two populations (Whyte et al. 2000). Others investigated a
variable number tandem repeat (VNTR), rs408392 or
rs2637988 and found that the genotype distributions of the
VNTR and rs408392 were not significantly different between
patients and controls (Barlo et al. 2011; Hutyrova et al. 2002;
Riha et al. 2004). However, in the largest of these studies, a
trend was observed with rs408392, and rs2637988 was found
to be significantly associated with IPF susceptibility (Barlo et
al. 2011). In a rare disease like IPF, validation of genetic
associations is hampered by the small sample size of available
cohorts. To establish whetherIL1RN is associated with therisk
of IPF, we performed a meta-analysis of the five case–control
studies.Althoughthesefivestudiesinvestigateddifferentpoly-
morphisms, they could be combined in a meta-analysis be-
cause the polymorphisms are in tight linkage disequilibrium.
At present, it is unclear how polymorphisms in IL1RN
predispose to disease. To compare the functional effects before
disease onset, we determined genotype-dependent mRNA ex-
pression for the VNTR and rs2637988 in healthy controls.
Material and methods
Study selection
For this meta-analysis, we included all five case–control
studies that investigated the association between polymor-
phisms in IL1RN and IPF in Caucasian populations (Table 1).
In the English population, rs419598 (chromosome position
113887207) was determined in 88 patients and 88 controls
(Whyte et al. 2000). The same SNP, rs419598, was deter-
mined in the Italian population in 61 patients and 103 controls
(Whyte et al. 2000). In the Czech population, the VNTR
(chromosome position 113888106) was determined in 54
patients and 199 controls (Hutyrova et al. 2002). The VNTR
was also determined in the Australian population in 22
patients and 140 controls, but only allele frequencies were
given and no individual genotypes were available (Riha et al.
2004). In the Dutch population, rs408392 (chromosome posi-
tion 113887458) and rs2637988 (chromosome position
113876779) were determined in 77 patients and 349 controls
(Barlo et al. 2011). In total, allele frequencies were available
for 302 patients with IPF and 879 controls. Individual geno-
types were available for 280 patients and 739 controls.
The VNTR (rs2234663) and rs408392 are located in
intron 2 (identical to intron 3 in the extended gene encoding
the intracellular isoform of IL-1Ra (Raitala et al. 2006));
rs419598 is located at position +2018 in exon 2. rs2637988
is located upstream of IL1RN near several transcription
factor binding sites.
The studies were identified using a PUBMED search
using the terms ‘polymorphism’, ‘Genetic association’,
‘pulmonary fibrosis’ and ‘fibrosing alveolitis’.O n l ys t u d i e s
on idiopathic pulmonary fibrosis (also called cryptogenic
fibrosing alveolitis) were included. One study was not a
case–control study but onlyreportedassociationswithdisease
phenotype and was excluded (Vasakova et al. 2007).
The populations included in this study were tested for
allelic association with disease (Table 1) using Pearson’s
goodness-of-fit chi-square as implemented online at http://
ihg2.helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl.T h i s
could not be done for the Australian population because
individual genotypes were not available, and therefore, we
included the p value as reported in their study in Table 1.
Measurement of linkage disequilibrium
We investigated the linkage disequilibrium between the
VNTR, rs419598, rs408392 and rs2637988. Because there
Table 1 Characteristics of the association studies on IL1RN and IPF
Study Origin of cohort Patients (n) Controls (n) Polymorphism RAF
patients
RAF
controls
p value
(allelic association)
Whyte et al. (2000a) Britain 88 88 rs419598 0.28 0.17 0.02
Whyte et al. (2000b) Italy 61 103 rs419598 0.33 0.20 0.01
Hutyrova et al. (2002) Czech Rep. 54 199 VNTR 0.31 0.30 0.90
Riha et al. (2004) Australia 22 140 VNTR 0.23 0.25 0.77
Barlo et al. (2011) The Netherlands 77 349 rs408392 0.32 0.26 0.09
rs2637988 0.47 0.38 0.04
RAF risk allele frequency, NA not available
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the genotypes for the VNTR, rs408392 and rs2637988 in
the Dutch cohort of 349 healthy controls (Table 1). Geno-
types for rs408392 and rs2637988 were retrieved from the
study by Barlo et al. (2011). The VNTR polymorphism was
determined by polymerase chain reaction (PCR). Primers
for the VNTR region were sense 5′-ACTCATGGCCTTG
TTCATT and antisense 5′-AAAACTAAAATCCC
GAGGTC (Sigma-Aldrich, St. Louis, MO, USA). PCR
products were run on a 1.5% agarose gel. A 25- and a
200-base pair ladder were used to discern the number of
86-base pair repeats. The VNTR includes a variable number
of repeats. The VNTR allele 2 (VNTR*2) is the shortest
withonlytworepeats.Theotherallelescorrespondtobetween
three and six repeats.
Because rs419598 was not determined in the Dutch
population, genotypes for the European HapMap popu-
lation were retrieved for rs408392 and rs419598. We
determined the linkage disequilibrium using the computer
program Haploview 4.1 (Broad Institute of MITand Harvard,
USA).
Meta-analysis
For the meta-analysis, we combined the case–control data
from the VNTR, rs408392 and rs419598 (+2018) in IL1RN
(Table 2) from five populations. The case and control
populations were tested for violation of Hardy–Weinberg
equilibrium.
The meta-analysis was performed using R software (ver-
sion 2.9.2, Catmap package, version 1.6, www.r-project.org).
Both a random effects (DerSimonian and Laird method) and a
fixed effects analysis (Mantel–Haenszel method) of the case–
control data were performed. To test for heterogeneity, the
Cochrane Q test and I
2 was used. In addition, a leave-one-out
sensitivity analysis was performed. When all five populations
were combined, we could only use an allele-based model
because individual genotypes were not available for the
Australian population. To investigate whether the risk allele
has a dominant or recessive influence on disease development
inthepopulation,bothmodelsweretested.Duetotheabsence
of individual genotypes, the Australian population was re-
moved and the remaining number of individuals carrying
one or more risk alleles was used in the analysis.
RNA expression
We used thawed peripheral blood mononuclear cells
(PBMC) from 38 healthy controls (23 males and 15 females,
mean age 22.5 years). The expression of IL1RN mRNAwas
analysed by quantitative RT-PCR amplification as described
previously (Heron et al. 2009). Briefly, total RNA was
isolated using an RNeasy microkit (Qiagen, Venlo, The
Netherlands) and cDNA was made using the I-script cDNA
synthesis kit (Bio-Rad, Veenendaal, The Netherlands). Pri-
mers used for expression analysis of IL1RN were forward
5′-GAAGATGTGCCTGTCCTGTGTC and reverse 5′-
CGCTTGTCCTGCTTTCTGTTC (Sigma-Aldrich). The
copy numbers were normalised by the housekeeping gene
β-actin (forward 5′-AGCCTCGCCTTTGCCGA and re-
verse 5′-CTGGTGCCTGGGGCG). SPSS and GraphPad
Prism software were used to test whether RNA expression
differed per genotype. A difference with a p<0.05 was
considered statistically significant.
Results
Measurement of linkage disequilibrium
Analysis of European HapMap population genotypes
showed that the two biallelic SNPs rs408392 and rs419598
are in complete linkage disequilibrium (D′ 0 1). There was
tight linkage disequilibrium between the VNTR and
rs408392 in our Dutch control population (D′ 0 0.99,
Fig. 1). We observed in the Dutch cohort, that in all indi-
viduals, the longer VNTR alleles with three or more repeats
corresponded completely to the major allele of rs408392
and of rs419598, while the VNTR*2 allele corresponded
to the minor alleles of these SNPs.
Table 2 Data used in the
meta-analysis
Alleles refers to the number of
alleles in the population; carriers
refers to the number of individ-
uals carrying the risk allele
NA not available
Allele frequency model Dominant model
Risk alleles/non-risk
alleles (n)
Risk carriers/non-risk
carriers (n)
Study Origin of cohort Patients Controls Patients Controls
Whyte et al. (2000a) Britain 49/127 30/146 39/49 28/60
Whyte et al. (2000b) Italy 40/82 42/164 35/26 37/66
Hutyrova et al. (2002) Czech Rep. 33/75 119/279 27/27 96/103
Riha et al. (2004) Australia 10/34 70/210 NA NA
Barlo et al. (2011) The Netherlands 50/104 180/518 43/34 155/194
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a haploblock, and for analysis, we combined the linked
alleles: we named the combination of risk alleles ‘VNTR*2
haploblock’ and this contained the VNTR*2 and the minor
alleles of rs419598 and rs408392.
Linkage disequilibriumbetween rs2637988 and the VNTR
(D′ 0 0.90) and between rs2637988 and rs408392 (D′ 0 0.94)
was high (Fig. 1), but the difference in frequencies between
the coupled alleles was substantial, and therefore, rs2637988
was not included in the meta-analysis.
Meta-analysis
The data used for the meta-analysis are shown in Table 2.
Cases and controls were individuals of European ancestry
from Britain, Italy, Czech Republic, Australia and The
Netherlands. The genotypes from all populations were in
Hardy–Weinberg equilibrium. Pooling of the populations
resulted in a risk allele frequency of the VNTR*2 haplo-
b l o c ko f0 . 3 0i np a t i e n t s( n0302) and 0.25 in controls
(n0879).
A significant association between the VNTR*2 haplo-
block and IPF was observed using an allele frequency
model with a fixed effects meta-analysis. The pooled
odds ratio (OR) was 1.42 (95% confidence interval (CI)
1.14–1.76, p00.002, χ
209.93) (Fig. 2). Sensitivity anal-
ysis showed that the association remained significant after
sequential removal of each one of the studies. Cochrane
Q test indicated there was no significant variability/heteroge-
neity among the studies in this meta-analysis (χ
205.2, p0
0.27). The I
2 was 23%, indicating that inconsistency across
studies was low. Although no heterogeneity was seen across
studies, the random effect models were run and ORs and CIs
were almost identical to thoses e e ni nt h ef i x e de f f e c t s
analysis.
Under the dominant genetic model, comparing non-
carriers to carriers of the VNTR*2 haploblock, the pooled
OR was 1.60 (95% CI 1.20–2.14, p00.002, χ
2010.01)
under a fixed effects assumption. The relative risk to devel-
op IPF for an individual carrying the VNTR*2 haploblock
was 1.29 (95% CI 1.05–1.57, p00.01) based on the four
populations in this analysis. The recessive genetic model
compares carriers of the VNTR*1 haploblock with homo-
zygous carriers of VNTR*2 haploblock and did not result in
a significant association.
mRNA expression analysis
We analysed IL-1Ra mRNA expression in relation to IL1RN
genotypes. A dosage effect tendency of the VNTR poly-
morphism on IL1RN mRNA expression is shown in Fig. 3,
but this did not reach significance (p00.30). Rs2637988
A/G was significantly associated with a difference in IL-
1Ra mRNA expression levels in healthy PBMC (Fig. 3).
Significantly lower mRNA expression levels were found in
control subjects with the minor GG genotype compared to
controls with the AG genotype (p<0.05) or the AA genotype
(p<0.001).
Fig. 1 Linkage plot for polymorphisms in IL1RN showing D′
Fig. 2 Fixed effects meta-analysis with an allele frequency model of
the effect of IL1RN on IPF susceptibility. Individual study odds ratios
(ORs) are shown as well as the pooled OR for the VNTR*2 haploblock
(VNTR, rs408392, rs419598). The pooled OR was 1.42 (CI 1.14–1.76,
p00.002)
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This meta-analysis showed that variations in IL1RN are
significantly associated with an increased risk of developing
IPF. In our linkage analysis, we found that there was tight
linkage disequilibrium between the VNTR, rs408392 and
rs419598, allowing the polymorphisms to be combined into
a VNTR*2 haploblock for the meta-analysis of five IPF
populations. The pooled odds ratio of the allele frequency
model showed that the VNTR*2 haploblock was signifi-
cantly associated with IPF. However, in the Italian and
Dutch populations, the largest association was reported for
carriership of the minor allele, corresponding to the
VNTR*2 haploblock (Barlo et al. 2011;W h y t ee ta l .
2000). With a dominant genetic model, the meta-analysis
showed an even stronger association with IPF than with the
allelic model (OR01.60 vs. OR01.42). This confirms that
carriership of the risk allele was most associated with IPF.
Individuals that are homo- or heterozygous for the risk allele
are at an increased risk of developing IPF. Calculation of the
relative risk showed that carriership of the risk allele confers
a 29% increasein the riskof developingIPF. Only individuals
without a risk allele, the majority of the population, are pro-
tected from developing IPF.
The effects of IL-1 are mediated by two protein isoforms,
IL-1α and IL-1β, who act through binding to the IL-1
receptor. Their effects are counterbalanced by the IL-1Ra
protein that binds to the receptor but does not transduce any
signal. The IL-1 effector response is determined by the
balance between these proteins (Barksby et al. 2007;
Ludwiczek et al. 2004; Sekiyama et al. 1994). The ratio
between IL1-Ra and IL-1 was found to be lower in serum
from IPF patients and in macrophages from IPF lungs (Barlo
etal.2011;Mi ku ni yaetal .1997).Previousstudieshavefound
that the IL-1Ra/IL-1 ratio is influenced by genetic variations
in IL1RN (Barlo et al. 2011; Carter et al. 2004). Higher IL-1
proteinlevelswerefoundingastricmucosafromHelicobacter
pylori-infected individuals that carried VNTR*2 (Garcia-
Gonzalez et al. 2009), while lower IL-Ra protein levels were
found in biopsies from ulcerative colitis patients with
VNTR*2 (Carter et al. 2004). Together, this indicates that
carriers of VNTR*2 have low levels of IL-1Ra but higher
IL-1 levels. The VNTR is a variation in an 86-base pair repeat
in an intron of the IL1RN gene. The change in mRNA length
caused by the VNTR could have an effect on its processing
and stability. Analysis of IL1RN mRNA expression in healthy
controls showed that there was a suggestive effect of the
VNTR polymorphism (and thus rs408392 and rs419598),
butthis did not reach significance. The dosageeffectobserved
for the VNTR might be caused by linkage to rs2637988
because rs2637988 is in nearly complete linkage disequilibri-
um with the VNTR. We found that rs2637988 GG was sig-
nificantly associated with lower IL1RN mRNA expression. In
addition, in the study by Barlo et al., the rs2637988 G allele
was significantly associated with IPF susceptibility (OR0
1.95) whereas rs408392 showed only a trend towards signif-
icance (Barlo et al. 2011). Together, this indicates that the
IL1RN rs2637988 polymorphism might have a greater effect
on IPF disease development than the VNTR*2 haploblock.
ThestudybyBarloetal.(2011)alsoshowedthatrs2637988 G
Fig. 3 The effect of IL1RN genotype on mRNA expression. IL-1Ra
mRNA expression in PBMC from healthy controls normalised to actin
expression. There was no significant effect of IL1RN VNTR genotype
on mRNA expression. A significant association between rs2637988
and mRNA expression was found. Error bars represent standard error
of the mean. VNTR*1 corresponds to four repeats and VNTR*2
corresponds to two repeats of the VNTR polymorphism
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hancedexpressionofIL-1βhasbeenfoundinalveolarmacro-
phages and pneumocytes in patients with acute pulmonary
fibroticdiseases(Panetal.1996).InanimalmodelsofIPF,IL-
1β levels are elevated in mice with bleomycin-induced lung
fibrosis (Gasse et al. 2007; Hoshino et al. 2009). Blocking the
IL-1 receptor with IL-1Ra reduced bleomycin-induced in-
flammation and prevented fibrosis in these mice (Gasse et al.
2007; Piguet et al. 1993). Transient overexpression of IL-1β
causedacutelunginjuryresultinginpulmonaryfibrosisinrats
(Kolbetal.2001).Thus,relativelylowlevelsofIL-1Rawould
failtopreventthepro-fibroticfunctionsofIL-1,andthiscould
play an important role in IPF disease aetiology. In light of
these findings, treatment of IPF patients with an IL-1 antago-
nist, like anakinra, should be considered. So far, treatment
with IL-1 blocking agents has been safe and effective in
rheumatoid arthritis, although the increased risk of respiratory
infection may mean caution is called for (Geyer and Muller-
Ladner 2010). In addition, it is possible that genetic variations
intheIL1AandIL1Bgenesalsoinfluencethebalancebetween
IL-1 and IL-1Ra and could therefore play a role in IPF suscep-
tibility. Future studies are needed to evaluate the role of poly-
morphisms in thesegenes andtheirinteractionwith eachother.
In conclusion, our meta-analysis shows that polymor-
phisms associated with the IL1RN VNTR increase suscepti-
bility to IPF. The IL1RN risk allele is associated with lower
levels of IL-1Ra. After the recent association of the MUC5B
gene with IPF (Seibold et al. 2011), this is the second largest
IPF association study. The role of IL-1Ra in preventing fibro-
sis supports the notion that insufficiently expressed IL-1Ra
can permit fibrogenesis to occur, thereby predisposing to IPF.
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